
## Samuel Levy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1318361/publications.pdf Version: 2024-02-01



SAMILEI LEVA

#	Article	IF	CITATIONS
1	Cardiovascular Adverse Events Associated with Energy Drinks in Adolescents and Young Adults. Cardiovascular Drugs and Therapy, 2022, 36, 379-381.	1.3	2
2	Management of atrial fibrillation: two decades of progress — a scientific statement from the European Cardiac Arrhythmia Society. Journal of Interventional Cardiac Electrophysiology, 2022, 65, 287-326.	0.6	20
3	Vernakalant for Rapid Cardioversion of Recent-Onset Atrial Fibrillation: Results from the SPECTRUM Study. Cardiovascular Drugs and Therapy, 2021, 35, 283-292.	1.3	10
4	Cardioversion of recentâ€onset atrial fibrillation using intravenous antiarrhythmics: A European perspective. Journal of Cardiovascular Electrophysiology, 2021, 32, 3259-3269.	0.8	2
5	Clinical classification and the subclinical atrial fibrillation challenge: a position paper of the European Cardiac Arrhythmia Society. Journal of Interventional Cardiac Electrophysiology, 2020, 59, 495-507.	0.6	6
6	European Cardiac Arrhythmia Society Statement on the cardiovascular events associated with the use or abuse of energy drinks. Journal of Interventional Cardiac Electrophysiology, 2019, 56, 99-115.	0.6	25
7	Acknowledgment and tribute to Dr. Sanjeev Saksena, Editor-in-Chief of the Journal of Interventional Cardiac Electrophysiology (JICE). Journal of Interventional Cardiac Electrophysiology, 2019, 55, 5-6.	0.6	0
8	Bundle branch blocks and/or hemiblocks complicating acute myocardial ischemia or infarction. Journal of Interventional Cardiac Electrophysiology, 2018, 52, 287-292.	0.6	7
9	Clinical presentation of inappropriate sinus tachycardia and differential diagnosis. Journal of Interventional Cardiac Electrophysiology, 2016, 46, 33-41.	0.6	15
10	Newer clinically available antithrombotics and their antidotes. Journal of Interventional Cardiac Electrophysiology, 2014, 40, 269-275.	0.6	9
11	Recent Atrial Fibrillation Guidelines – Looking at Both Sides of the Atlantic. Arrhythmia and Electrophysiology Review, 2013, 2, 8.	1.3	0
12	ECG repolarization syndrome abnormalities (J wave syndromes) and idiopathic ventricular fibrillation. Journal of Interventional Cardiac Electrophysiology, 2011, 32, 181-186.	0.6	9
13	Current atrial fibrillation guidelines and therapy algorithms: Are they adequate?. Journal of Interventional Cardiac Electrophysiology, 2009, 25, 111-116.	0.6	3
14	Effect of Ivabradine, a Novel Antianginal Agent, on Driving Performance. Clinical Drug Investigation, 2009, 29, 339-348.	1.1	2
15	Increased Mortality after Dronedarone Therapy for Severe Heart Failure. New England Journal of Medicine, 2008, 358, 2678-2687.	13.9	901
16	Do we need pharmacological therapy for atrial fibrillation in the ablation era?. Journal of Interventional Cardiac Electrophysiology, 2007, 17, 189-194.	0.6	8
17	Drug Insight: angiotensin-converting-enzyme inhibitors and atrial fibrillation—indications and contraindications. Nature Clinical Practice Cardiovascular Medicine, 2006, 3, 220-225.	3.3	17
18	Internal Defibrillation: Where we Have Been and Where we Should be Going?. Journal of Interventional Cardiac Electrophysiology, 2005, 13, 61-66.	0.6	14

SAMUEL LEVY

#	Article	IF	CITATIONS
19	Atrial fibrillation management: a prospective survey in ESC Member Countries. European Heart Journal, 2005, 26, 2422-2434.	1.0	770
20	Intra-atrial thrombosis and pulmonary embolism complicating pacemaker leads for cardiac resynchronization therapy. Journal of Interventional Cardiac Electrophysiology, 2003, 9, 25-27.	0.6	5
21	International Consensus on Nomenclature and Classification of Atrial Fibrillation: A Collaborative Project of the Working Group on Arrhythmias and the Working Group of Cardiac Pacing of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Journal of Cardiovascular Electrophysiology, 2003, 14, 443-445.	0.8	81
22	Atrial fibrillation, the arrhythmia of the elderly, causes and associated conditions. Anatolian Journal of Cardiology, 2002, 2, 55-60.	0.4	11
23	approved by the American College of Cardiology Board of Trustees in August 2001, the American Heart Association Science Advisory and Coordinating Committee in August 2001, and the European Society of Cardiology Board and Committee for Practice Guidelines and Policy Conferences in August 2001.32When citing this document, the American College of Cardiology, the American Heart	1.2	62
24	Association, and the European Society. Journal of the American College of Cardiology, 2001, 38, 1266. Inducible ventricular arrhythmias and patency of infarctâ€related artery in survivors of acute myocardial infarction. Clinical Cardiology, 2001, 24, 782-785.	0.7	0
25	Classification system of atrial fibrillation. Current Opinion in Cardiology, 2000, 15, 54-57.	0.8	52
26	Specific Up-Regulation of Mitochondrial F0F1-ATPase Activity after Short Episodes of Atrial Fibrillation in Sheep. Journal of Cardiovascular Electrophysiology, 2000, 11, 432-438.	0.8	15
27	Inhibition of Na,K-ATPase by External Electrical Cardioversion in a Sheep Model of Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 2000, 11, 439-445.	0.8	8
28	Spontaneous episodes of atrial fibrillation after implantation of the Metrix Atrioverter: observations on treated and nontreated episodes. Journal of the American College of Cardiology, 2000, 35, 1428-1433.	1.2	67
29	Antibodies Against Myosin in Sera of Patients with Idiopathic Paroxysmal Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 1998, 9, 612-617.	0.8	68
30	The Role of Antiarrhythmic Drugs in Patients With Implanted Cardioverter Defibrillators. Journal of Interventional Cardiology, 1998, 11, 213-216.	0.5	1
31	Multicenter Low Energy Transvenous Atrial Defibrillation (XAD) Trial Results in Different Subsets of Atrial Fibrillation. Journal of the American College of Cardiology, 1997, 29, 750-755.	1.2	170
32	Factors Predisposing to the Development of Atrial Fibrillation. PACE - Pacing and Clinical Electrophysiology, 1997, 20, 2670-2674.	0.5	79
33	Incidence of Perforation and Other Mechanical Complications During Dual Active Fixation. PACE - Pacing and Clinical Electrophysiology, 1996, 19, 1828-1831.	0.5	49
34	Sudden Death as a Presenting Symptom of Hypertrophic Cardiomyopathy: Treatment with an Implantable Cardioverter Defibrillator. PACE - Pacing and Clinical Electrophysiology, 1996, 19, 1264-1267.	0.5	2
35	Paroxysmal A trial Fibrillation: Journal of Cardiovascular Electrophysiology, 1995, 6, 69-74.	0.8	68
36	Direct recording of sinus node potentials using electrode catheter techniques. Clinical Cardiology, 1994, 17, 203-206.	0.7	1

SAMUEL LEVY

#	Article	IF	CITATIONS
37	Arrhythmias in the Mitral Valve Prolapse Syndrome: Clinical Significance and Management. PACE - Pacing and Clinical Electrophysiology, 1992, 15, 1080-1088.	0.5	18
38	Direct current cardioversion of established atrial fibrillation. Clinical Cardiology, 1992, 15, 445-449.	0.7	8
39	Internal Cardioversion of Chronic Atrial Fibrillation. Journal of Interventional Cardiology, 1990, 3, 53-58.	0.5	0
40	Efficacy of Hydroquinidine in Recurrent Ventricular Tachycardias. Journal of Electrophysiology, 1989, 3, 378-380.	0.5	1
41	Remote Occurrence of High Degree Heart Block Following Failure of Transcatheter AV Junctional Ablation: Incidence and Clinical Significance. PACE - Pacing and Clinical Electrophysiology, 1987, 10, 937-942.	0.5	1
42	Alternate Ventriculo-Atrial Wenckebach Conduction during Ventricular Tachycardia. PACE - Pacing and Clinical Electrophysiology, 1985, 8, 569-573.	0.5	0
43	Retrograde (Ventriculoatrial) Conduction. PACE - Pacing and Clinical Electrophysiology, 1983, 6, 364-371.	0.5	18
44	Bidirectional Tachycardia. Mechanism Derived from Intracardiac Recordings and Programmed Electrical Stimulation. PACE - Pacing and Clinical Electrophysiology, 1982, 5, 633-638.	0.5	15